Loading provider…
Loading provider…
Internal Medicine Physician in Boston, MA
NPI: 1376924571Primary Practice Location
BRIGHAM AND WOMEN'S HOSPITAL
75 Francis St, Boston, MA
Primary Employer
Dana-Farber Cancer Institute
dana-farber.org
HQ Phone
Get M.D., PH.D Daniel's Phone Numberphone_androidMobile
Get M.D., PH.D Daniel's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMA State Medical License
MA State Medical License
2015 - 2027
ME State Medical License
2024 - 2026

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Medical Oncology
Perelman School of Medicine - Philadelphia
med.upenn.edu
Medical School
Until 2015
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
Fellowship • Hematology and Medical Oncology
2017 - 2021
Mass General Brigham/Brigham and Women's Hospital
Residency • Internal Medicine
2015 - 2017
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 18 | 42 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 18 | 29 |
| 3 | G2212Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 13 | 22 |
| 4 | 99205New patient office or other outpatient visit, typically 60 minutes | 12 | 12 |
| 5 | 99231Subsequent hospital inpatient care, typically 15 minutes per day | 12 | 33 |
Inhibition of γ-Secretase Activity Inhibits Tumor Progression in a Mouse Model of Pancreatic Ductal Adenocarcinoma
Authors: Andrew Rhim, Aram Hezel
Publication Date: 2009-05
An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib.
Authors: Mark Awad
Publication Date: 2018-04